Abstract
We studied fracture risk associated with parkinsonism (including Parkinson’s disease) and drugs used to treat these conditions in a case-control study. Cases were all subjects with any fracture during the year 2000 (n = 124,655). For each case, three controls (n = 373,962) matched on age and gender were randomly drawn from the background population. Exposure was a diagnosis of parkinsonism or use of anticholinergic drugs, levodopa alone or in combination with carbidopa, and/or catechol-O-methyl transferase (COMT) inhibitors, dopamine agonists, or monoamine oxidase B (MAO-B) inhibitors and a number of other confounders. Parkinsonism was associated with a crude odds ratio (OR) of any fracture of 2.2 (95% confidence interval [95% CI] 2.0–2.5) and an adjusted OR of 1.2 (95% CI 1.0–1.4), the risk being higher especially in males younger than 75 years. Levodopa was associated with an increased overall fracture risk and an increased risk of hip fractures in high doses. Dopamine agonists, anticholinergic drugs, and MAO-B inhibitors were not associated with increased fracture risk except for hip fractures at high doses for MAO-B inhibitors and hip fractures at median doses for dopamine agonists. Neuroleptics were associated with increased risk of fractures in almost all skeletal sites and doses. In conclusion, parkinsonism was associated with increased risk of fractures, especially among males younger than 75 years, and the risk was significantly attenuated upon adjustment for confounders. Use of neuroleptics and, to some degree, levodopa was associated with increased risk of fractures.
Similar content being viewed by others
References
Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 34:21–24
Johnell O, Melton LJ III, Atkinson EJ, O’Fallon WM, Kurland LT (1992) Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38
Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ, Ensrud KE (2004) Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 52:1479–1486
Wielinski CL, Erickson-Davis C, Wichmann R, Walde-Douglas M, Parashos SA (2005) Falls and injuries resulting from falls among patients with Parkinson’s disease and other parkinsonian syndromes. Mov Disord 20:410–415
Williams DR, Watt HC, Lees AJ (2006) Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 77:468–473
Melton LJ III, Leibson CL, Achenbach SJ, Bower JH, Maraganore DM, Oberg AL, Rocca WA (2006) Fracture risk after the diagnosis of Parkinson’s disease: influence of concomitant dementia. Mov Disord 21:1361–1367
Yamanashi A, Yamazaki K, Kanamori M, Mochizuki K, Okamoto S, Koide Y, Kin K, Nagano A (2005) Assessment of risk factors for second hip fractures in Japanese elderly. Osteoporos Int 16:1239–1246
Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A (2006) Bone mineral density in hip-fracture patients with Parkinson’s disease: a case-control study. Arch Phys Med Rehabil 87:1459–1462
Taggart H, Crawford V (1995) Reduced bone density of the hip in elderly patients with Parkinson’s disease. Age Ageing 24:326–328
Sato Y, Kikuyama M, Oizumi K (1997) High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 49:1273–1278
Sato Y, Manabe S, Kuno H, Oizumi K (1999) Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:64–68
Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K (2002) Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency. Bone 31:114–118
Sato Y, Kaji M, Tsuru T, Oizumi K (2001) Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci 182:89–93
Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson’s disease. Am J Med 118:1250–1255
Dorrington J, Gore-Langton RE (1981) Prolactin inhibits oestrogen synthesis in the ovary. Nature 290:600–602
Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287:2398–2399
Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268
Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 156:1–10
Wacholder S, McLaughlin JK, Silverman DT, Mandel JS (1992) Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135:1019–1028
Capella D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug utilization studies: methods and uses. WHO Regional Publications, European Series 45, Copenhagen, pp 55–78
Nielsen GL, Sørensen HT, Zhou W, Steffensen FH, Olsen J (1997) The pharmaco-epidemiologic prescription database of north Jutland. Int J Risk Saf Med 10:203–205
Munk-Jørgensen P, Mortensen PB (1997) The Danish Psychiatric Central Register. Dan Med Bull 44:82–84
Miettinen OS (1985) Theoretical epidemiology: principles of occurrence research in medicine. Wiley, New York
Vestergaard P, Mollerup CL, Frøkjær VG, Christiansen P, Blichert-Toft M, Mosekilde L (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598–602
Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17:807–816
Ensrud KE, Blackwell TL, Mangione CM, Bowman PJ, Whooley MA, Bauer DC, Schwartz AV, Hanlon JT, Nevitt MC (2002) Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 50:1629–1637
Pollock BG (1999) Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 60 Suppl 20:4–8
Steiger MJ, Thompson PD, Marsden CD (1996) Disordered axial movement in Parkinson’s disease. J Neurol Neurosurg Psychiatry 61:645–648
Aita JF (1982) Why patients with Parkinson’s disease fall. JAMA 247:515–516
Sambrook PN, Cameron ID, Chen JS, Cumming RG, Lord SR, March LM, Schwarz J, Seibel MJ, Simpson JM (2007) Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 18:603–610
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vestergaard, P., Rejnmark, L. & Mosekilde, L. Fracture Risk Associated with Parkinsonism and Anti-Parkinson Drugs. Calcif Tissue Int 81, 153–161 (2007). https://doi.org/10.1007/s00223-007-9065-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-007-9065-6